DRKS00033796招募中不适用
The burden of recurrence for HR+/HER2- early breast cancer patients (VONKO-018) - VONKOdb Early stage BC 2024
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- ovartis
- 入组人数
- 30,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 120 Years（—）
- 性别
- All
入选标准
- •ICD-10 C50
- •- Diagnosis years: 2015-2023
- •- Place of residence in the federal state of the requested registry (population-based cases) at the time of diagnosis
排除标准
- •- Cancer case is known to the registry exclusively on the basis of
- •- a death certificate (DCO case)
- •- a pathology report
- •- a progress report
- •- a report on the tumor conference
- •- a combination of the aforementioned reporting types
- •- Previous tumor diagnosis up to 5 years before breast cancer
研究者
相似试验
招募中
1 期
Biomarker analysis in patients with metastatic breast cancer treated with sacituzumab govitecan.male or pre/post-menopausal women age = 18 years with locally advanced/metastatic HR+/HER2-negative BC resistant to ET + CDK4/6 inhibitors. No more than 1 prior systemic chemotherapy or ADC regimens for metastatic disease are permitted.CTIS2023-505385-28-00Solti Group50
招募中
不适用
CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast CancerBreast CancerHER2-negative Breast CancerHormone Receptor Positive Breast CarcinomaNCT05870813Institut fuer Frauengesundheit3,000
招募中
不适用
HIPEx (HIgh risk ER+HER2- T1-2N0-1 early breast cancer with Palbociclib plus Endocrine Therapy)NeoplasmsKCT0004553Samsung Medical Center578
尚未招募
2 期
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)Metastatic Breast CancerNCT05577923Fudan University126
已完成
不适用
A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of TherapyHR+/HER2- Advanced or Metastatic Breast CancerNCT05853432Novartis Pharmaceuticals157